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1. Introduction 2. Materials and methods 
There is good evidence that chromosome 21 car- 
ries the gene(s) that determines the sensitivity of 
human fibroblasts to the antiviral activities of inter- 
feron (Y, /3 [l-12] and y [8]. Furthermore, it has also 
been shown that the lymphocytes of patients with 
Down’s syndrome (trisomy for chromosome 21) were 
more sensitive to inhibition by interferon of lympho- 
blastogenesis after stimulation with phytohemagglu- 
tinin or allogenic cells, than lymphocytes disomic for 
chromosome 21 [ 13,141, and that cultured peripheral 
blood monocytes from these patients also showed an 
enhanced sensitivity to the maturation-inhibiting 
effect of leucocyte interferon [ 1.51. The use of anti- 
bodies raised against cells carrying chromosome 21 to 
block interferon action [ 71 and the increased recov- 
ery of interferon from interferon-treated human 
fibroblasts trisomic for chromosome 21 [9], sug- 
gested that the gene product responsible for increased 
interferon sensitivity might be a specific cell-surface 
receptor. 
With purified 12SI-labelled human interferon (Hu 
IFNo), we have demonstrated the presence of high- 
affinity receptor sites for Hu IFNa on a wide variety 
of lymphoid cells [ 161. Herein, we show that lym- 
phocytes from patients with Down’s syndrome show 
an increased specific binding of 1251-H~ IFNo com- 
pared to lymphocytes from normal donors. This 
study also provides norms for the affinity of binding 
and the interferon receptor concentration that may 
prove useful in investigating the interferon sensitivity 
of peripheral blood lymphocytes from patients with 
other diseases. 
2 1 ‘251-Labelled interferon . . 
The IFN was prepared [ 171, purified [ 181 and 
radiolabelled [ 161 as described. Two preparations of 
labelled interferon were used. The biological activity, 
protein content, radioactive incorporation, radio- 
active decay and the purity were controlled for each 
preparation. The Hu IFNa (derived from Namalwa 
cells) has been well characterized [ 19,201 and this 
allows us to make a conversion from cpm to mol 
interferon. Details of the calculation and the estima- 
tion of error has been described in [ 161. Briefly, for 
20 000 Mr and a specific biological activity of 2 X 10’ 
units/mg protein, a radioactive counting efficiency of 
80% and a mean incorporation of 1 r2’I/atom inter- 
feron molecule we obtain a value of 400 X 1016 cpm/ 
mol interferon (2.193 X 10 Ci/mol I; 1.8 X 1012 
cpm/Ci). Thus 400 cpm are equivalent to lo-r6 mol 
interferon: and 1000 cpm to 1 unit of interferon for 
100% incorporation of 12’I. We currently estimate the 
error at 925%. 
2.2. Lymphocytes and interferon binding 
Heparinized peripheral blood samples were obtained 
from 8 normal donors and 6 patients with Down’s 
syndrome (ages 1 l-1 8 years). All these patients were 
shown to be trisomic for chromosome 21. Lympho- 
cytes were separated on a Ficoll-Hypaque gradient. 
Depending upon the yield, lymphocytes were resus- 
pended at 0.5-2.0 X lo6 cells/ml and incubated with 
different concentrations of radiolabelled interferon at 
37’C for 90 min, equilibrium being attained within 
1 h [ 161. Washing and counting was done at 4°C as 
in [16]. 
Direct binding and Scatchard plots [21] were cal- 
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culated from the free interferon concentration and 
the specifically bound interferon, as in fig.1. The 
regression of the Scatchard plot was taken as linear, 
the intercept on the abscissa giving the maximum 
cpm bound (equivalent to the total number of recep- 
tor sites), and the reciprocal of the slope giving the 
free interferon concentration when half the sites are 
occupied (equivalent to the dissociation constant, 
K, for the interferon-receptor complex). 
3. Results and discussion 
Fig.1 shows the direct binding and Scatchard plots 
from one normal donor and one patient with Down’s 
syndrome and table 1 gives the mean values of the 
binding constants for the two groups. Lymphocytes 
from patients with Down’s syndrome have 3-times as 
many binding sites/cell compared to lymphocytes 
from normal donors. Furthermore, the binding sites 
on the lymphocytes from patients with Down’s syn- 
drome showed a higher affinity for Hu IFNa than 
did the binding sites on lymphocytes from normal 
donors. 
These results provide further evidence of a rela- 
tionship between chromosome 21 and the cellular 
receptor for Hu IFNa, suggesting that there may be a 
direct causal relationship between enhanced sensitiv- 
ity to interferon shown by 21-trisomic lymphocytes 
[ 13,141 and the enhanced values for the receptor 
binding constants. 
The values we have found for the binding con- 
stants of the normal lymphocytes correspond well 
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Fig.1. Direct binding graph and Scatchard representation 
(inset) for binding data from one normal donor (4-b) and 
one patient with Down’s syndrome (o-o). Bound Hu IFN 
(E) was calculated from radioactive counts bound to 10‘ cells 
(total cpm bound - cpm bound in presence of lOO-fold excess 
of unlabelled interferon). Free IFN concentration Q calcu- 
lated from radioactivity added (total cpm/ml added - cpm 
bound/ml culture). The symbols indicate the actual experi- 
mental values, and the curves were calculated from the linear 
regression of the Scatchard plots. 
Table 1 
A comparison of binding constants (37°C) for binding of Hu IFNo to peripheral 
lymphocytes from normal donors and patients with Down’s syndromea 
(Standard deviations in parenthesis) 
Donors No. of Mean Kdb Mean receptor densityC 
donors (X lo-” M) (X 1O-‘6 mol/lOb cells) 
Normal 8 5.20 (0.87) 4.80 (0.99) 
Down’s 6 3.36 (1.27) 14.50 (1.79) 
Significance (t-test) 
for difference of 
means p = 0.01 p < 0.001 
a Lymphocytes were incubated at 0.5-2.0 x lo6 cells/ml depending upon the 
yield from blood. We found no correlation between lymphocyte yield and the 
values for the binding constants 
b From the reciprocal of slope of Scatchard plot 
’ From intercept on the abscissa of Scatchard plot 
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with the estimates in [ 161. Similar &values were 
obtained from competition experiments with unla- 
belled interferon (unpublished) suggesting that the 
labelling procedure has not altered the affinity of 
binding. A mean K, of 5.0 X 10-l’ M (table 1) for 
binding to normal lymphocytes (at -1 O6 cells/ml) 
means that the half receptor sites are occupied at an 
interferon concentration of -200 units/ml and that 
saturation is approached at >lOOO units/ml. With 
1 site/molecule of Hu IFNa bound, there would be a 
mean of 300 receptors/lymphocyte. 
While it was not practical to use age-matched 
donors, we have tested occasional 21 -disomic donors 
that fall within the Down’s age group, and found 
binding in the range for normal donors. A value for 
receptor density on human cord lymphocytes also fell 
within the normal range. We feel that possible age or 
sex-related differences in receptor expression by nor- 
mal 21 -disomic lymphocytes would only be revealed 
among a much larger number of donors than has suf- 
ficed to point out the difference in this study. 
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